Welldoc Submits 510(k) for Bolus and Premixed Insulin Titration Program as Part of BlueStar®
Welldoc Submits 510(k) for Bolus and Premixed Insulin Titration Program as Part of BlueStar® Welldoc Submits 510(k) for Bolus and Premixed Insulin Titration Program as Part of BlueStar® Welldoc, a trailblazer in digital health that is revolutionizing chronic condition management to help transform lives, today announced the filing of its ninth 510(k) with the U.S. Food and Drug Administration (FDA) for BlueStar, an FDA-cleared digital health solution for diabetes. With the filing, BlueStar looks to add bolus and premixed insulin titration for type 2 diabetes to its comprehensive diabetes pl...
Source: globalbankingandfinance.com